MMR Vaccines - The MMR vaccine is an immunization vaccine against Measles, Mumps, and Rubella (German measles). The vaccine contains a mixture of live attenuated viruses of three diseases, administered together parentally. MMR vaccine was first developed by Maurice Hilleman. MMR is a two-shot series of vaccines usually given during childhood. The first dose of vaccine is to be given when between 12-15 months of age, and the second dose at an age of 4-6 years.

CDC recommends that people get MMR vaccine to protect against measles, mumps, and rubella. Children should get two doses of MMR vaccine, starting with the first dose at 12 to 15 months of age, and the second dose at 4 through 6 years of age. Teens and adults should also be up to date on their MMR vaccination. Children may also get MMRV vaccine, which protects against measles, mumps, rubella, and varicella (chickenpox). This vaccine is only licensed for use in children who are 12 months through 12 years of age.

Who should not get the vaccine

Measles, Mumps, and Rubella (MMR) vaccine

Some people should not get MMR vaccine or should wait.

Tell your vaccine provider if the person getting the vaccine:

• Has any severe, life-threatening allergies. A person who has ever had a life-threatening allergic reaction after a dose of MMR vaccine, or has a severe allergy to any part of this vaccine, may be advised not to be vaccinated. Ask your health care provider if you want information about vaccine components.
• Is pregnant, or thinks she might be pregnant. Pregnant women should wait to get MMR vaccine until after they are no longer pregnant. Women should avoid getting pregnant for at least 1 month after getting MMR vaccine.
• Has a weakened immune system due to disease (such as cancer or HIV/AIDS) or medical treatments (such as radiation, immunotherapy).

Conclusion

Our Journal is planning to release a year end special issue to celebrate its journey for publishing articles with in the short time.

 A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing.

Manuscripts can be forwarded to the Editorial Office at autoimmunedis@eclinicalsci.com

How we work:

• After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
• A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
• Author proof is generated within 7 working days after the acceptance decision.

Benefits on Publication:

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

Color Art: In a world of black & white journal articles, high-quality full-color images make your article stand out from the crowd and tell a complete story, increasing readers and citations.

Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.

Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.

Media Contact:
John Kimberly
Assistant Editorial Manager
Journal of Vaccines & Vaccination
Email: jvv@scholarlypub.com